Healthcare entity
Across a 22-day span, the pace is roughly 1.3 stories per week. The busiest single day carried 3. Coverage clusters in regulation, which accounts for 3 of those 4, with the remainder spread across 1 other category. Therapeutic Goods Administration (TGA) is most often covered alongside Australasian Menopause Society, which appears in 1 of these 4 stories.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Across a 22-day span, the pace is roughly 1.3 stories per week. The busiest single day carried 3. Coverage clusters in regulation, which accounts for 3 of those 4, with the remainder spread across 1 other category. Therapeutic Goods Administration (TGA) is most often covered alongside Australasian Menopause Society, which appears in 1 of these 4 stories. Source depth averages 2.5 original sources per story, versus 3.2 across the same-window beat baseline. At 6, the average consequence score sits above the same-window beat average of 5.9. Therapeutic Goods Administration (TGA) appears in 4 tracked Healthcare stories published from February 27, 2026 through March 20, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 434 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Therapeutic Goods Administration (TGA). Shared-story counts are live from our verified record — not editorial picks.
TGA Approval
Australian regulators approve the Virtual Nodule Clinic for clinical use.
Public Advocacy Surge
Increased media coverage and patient advocacy highlight the pricing disparity between genders.
Series A Funding
Company raises $14M to scale global commercial operations.
FDA Clearance
Optellum receives first-of-its-kind FDA clearance for lung cancer AI.
TGA Approval
The Therapeutic Goods Administration approves the first female-specific testosterone cream.
Global Consensus Statement
International medical societies reach consensus on testosterone use for women's sexual health.
The public endorsement of medicinal cannabis by patients like Bilal Cassim for PTSD and insomnia highlights a significant shift in Australian healthcare toward cannabinoid therapies. This trend reflects a broader move toward alternative mental health treatments as the clinical and regulatory landscape continues to evolve.
The Australian government is significantly reducing funding for expensive spinal cord stimulators following reports linking the devices to severe patient injuries. This regulatory shift follows a clinical review that found the high-cost implants often provide no long-term benefit over conservative care.
Australian women are facing significant financial barriers to accessing testosterone therapy, often paying substantially more than men for the same hormone treatment. While the therapy is clinically recognized for treating sexual dysfunction in postmenopausal women, the lack of subsidized options highlights a systemic gap in the national pharmaceutical framework.
Source: theage.com.au · brisbanetimes.com.au
Optellum has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. This expansion allows Australian clinicians to utilize advanced imaging analytics to improve early lung cancer detection and streamline patient care pathways.
Source: singaporestar.com · asiabulletin.com
Therapeutic Goods Administration (TGA) is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
